(8S,10S)-10-(((2R,4S,R,S)-4-氨基-- | (8S,10S)-10-(((2R,4S,R,S)-4-Amino | - 亚薄世界杯试剂

：纯度：98% CAS：

英文名称：(8S,10S)-10-(((2R,4S,R,S)-4-Amino--hydroxy--methyltetrahydro-2H-pyran-2-yl)oxy)-,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-,-dione hydrochloride (Doxorubicin Impurity)

规格	目录价格	上海	安徽	武汉	成都	北方	深圳	会员价格	数量
2mg	请询价	--	--	--	--	--	--	--	- +
0mg	请询价	--	--	--	--	--	--	--	- +
100mg	请询价	--	--	--	--	--	--	--	- +
20mg	请询价	--	--	--	--	--	--	--	- +

大包装咨询

推荐产品

产品名称：(8S,10S)-10-(((2R,4S,S,S)-4-Amino--hydroxy--methyltetrahydro-2H-pyran-2-yl)oxy)-,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-,-dione hydrochloride (Doxorubicin Impurity) 纯度：98%

：18299

CAS号：231-40-9

￥ ƃƛŵŞǑǑ /100mg

￥ ƥȐŵŞǑǑ /20mg

￥ ŵǶƃŞǑǑ /1g

￥ ƛȡȐƃŞǑǑ /g

￥ ŵƛǑǑŞǑǑ /10g

￥ ƃȡȐƥƥŞǑǑ /2g

货期咨询

基本信息
属性
计算化学
参考文献
安全信息

英文名称

(8S,10S)-10-(((2R,4S,R,S)-4-Amino--hydroxy--methyltetrahydro-2H-pyran-2-yl)oxy)-,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-,-dione hydrochloride (Doxorubicin Impurity)

英文别称

中文别称

Smiles Code

OC1=C(C(C2=CC=CC(OC)=C2C3=O)=O)C3=C(O)C4=C1C[C@](C(CO)=O)(O)C[C@@H]4O[C@H]C[C@@H]([C@H]([C@@H](O)C)O)N.Cl

分子式

C27H30ClNO11

纯度

98%

细胞渗透性蒽环类抗肿瘤抗生素。抗肿瘤。阿霉素的立体异构体，具有降低的心脏毒性。其抗肿瘤作用是通过靶向拓扑异构酶 II 介导的。

展开

20.07

[1]. Ananth Shankar, et al. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy. Br J Haematol. 2014 May;1(4):34-44.

[2]. Bj?rn Naume, et al. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer. J Clin Oncol. 2014 Dec 1;32(34):3848-7.

[3]. Chih-Wen Twu, et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):21-9.

[4]. Francesco Russo, et al. The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC0) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. BMC Cancer. 2013 Feb 4:13:.

[]. Jude M Mulligan, et al. Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer. J Natl Cancer Inst. 2014 Jan;10(1):djt33.